A new vitamin K epoxide reductase complex subunit-1 (VKORC1) mutation in a patient with decreased stability of CYP2C9 enzyme

被引：31
作者：
D'Ambrosio, R. L.
D'Andrea, G.
Cafolla, A.
Faillace, F.
Margaglione, M.
机构：
[1] Univ Roma La Sapienza, Dept Haematol, Rome, Italy
[2] IRCCS Casa Sollievo della Soerenza, Unita Aterosclerosi & Trombosi, Rome, Italy
[3] Univ Studi Foggia, Dipartimento Sci Biomed, Cattedra Genet Med, I-71100 Foggia, Italy
来源：
JOURNAL OF THROMBOSIS AND HAEMOSTASIS | 2007年 / 5卷 / 01期
关键词：
D O I：
10.1111/j.1538-7836.2006.02261.x
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：191 / 193
页数：4
相关论文
共 8 条
[1]   Discovery of new potentially defective alleles of human CYP2C9 [J].
Blaisdell, J ;
Jorge-Nebert, LF ;
Coulter, S ;
Ferguson, SS ;
Lee, SJ ;
Chanas, B ;
Xi, T ;
Mohrenweiser, H ;
Ghanayem, B ;
Goldstein, JA .
PHARMACOGENETICS, 2004, 14 (08) :527-537
[2]   A vitamin K epoxide reductase complex subunit-1 (VKORC1) mutation in a patient with vitamin K antagonist resistance [J].
Bodin, L ;
Horellou, MH ;
Flaujac, C ;
Loriot, MA ;
Samama, MM .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2005, 3 (07) :1533-1535
[3]   A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin [J].
D'Andrea, G ;
D'Ambrosio, RL ;
Di Perna, P ;
Chetta, M ;
Santacroce, R ;
Brancaccio, V ;
Grandone, E ;
Margaglione, M .
BLOOD, 2005, 105 (02) :645-649
[4]   Vitamin K epoxide reductase: homology, active site and catalytic mechanism [J].
Goodstadt, L ;
Ponting, CP .
TRENDS IN BIOCHEMICAL SCIENCES, 2004, 29 (06) :289-292
[5]   Pharmacodynamic resistance to warfarin associated with a Val66Met substitution in vitamin K epoxide reductase complex subunit I [J].
Harrington, DJ ;
Underwood, S ;
Morse, C ;
Shearer, MJ ;
Tuddenham, EGD ;
Mumford, AD .
THROMBOSIS AND HAEMOSTASIS, 2005, 93 (01) :23-26
[6]   IMPAIRED (S)-WARFARIN METABOLISM CATALYZED BY THE R144C ALLELIC VARIANT OF CYP2C9 [J].
RETTIE, AE ;
WIENKERS, LC ;
GONZALEZ, FJ ;
TRAGER, WF ;
KORZEKWA, KR .
PHARMACOGENETICS, 1994, 4 (01) :39-42
[7]   Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2 [J].
Rost, S ;
Fregin, A ;
Ivaskevicius, V ;
Conzelmann, E ;
Hörtnagel, K ;
Pelz, HJ ;
Lappegard, K ;
Seifried, E ;
Scharrer, I ;
Tuddenham, EGD ;
Müller, CR ;
Strom, TM ;
Oldenburg, J .
NATURE, 2004, 427 (6974) :537-541
[8]   In-vitro and in-vivo effects of the CYP2C9*11 polymorphism on warfarin metabolism and dose [J].
Tai, GY ;
Farin, F ;
Rieder, MJ ;
Dreisbach, AW ;
Veenstra, DL ;
Verlinde, CLMJ ;
Rettie, AE .
PHARMACOGENETICS AND GENOMICS, 2005, 15 (07) :475-481
1